Manufacture of basic pharmaceutical products and pharmaceutical preparations
Filed accounts
NACE 21100 · financial year 2025 · 109 filed annual accounts| Per financial year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Median solvency | 32.1% | 37.6% | 36.9% | 37.9% | 40.8% | 39.2% |
| Median net result | €12,702 | €14,742 | €6,934 | €10,515 | €8,621 | €8,208 |
Hold your customer's or competitor's figures against them in the Sector benchmark
Bankruptcies
Recent bankruptcies
| Date | Company |
|---|---|
| 10-03-2026 | Amalus Therapeutics
BE 0803.929.268 |
| 27-10-2025 | UNIZIMA
BE 0744.643.759 |
Spread across the country
by region and province · 137 of 146 enterprises with a registered office on file · a sole trader has no published seat- Flanders
- Wallonia
- Brussels
- Abroad
The balance sheets of division 21 on the map, by municipality and down to the address
Largest employers
NACE 21100 as first main activity · staff from the latest accounts- 1 BAXALTA BELGIUM MANUFACTURINGLessines 1,197 FTEfinancial year 2026
- 2 AJINOMOTO OMNICHEMWetteren 863 FTEfinancial year 2026
- 3 PolyPeptideBraine-l'Alleud 485 FTEfinancial year 2025
- 4 Prothya Biosolutions BelgiumBrussels 349 FTEfinancial year 2026
- 5 Catalent GosseliesCharleroi 147 FTEfinancial year 2025
Joint committees
from the latest accounts of 46 companies- 207 White-collar workers in the chemical industry 32
- 116 Chemical industry 18
- 200 Auxiliary committee for white-collar workers 8
- 313 Pharmacies and pricing offices 2
- 209 White-collar workers in metal manufacturing 1
- 302 Hotels and catering 1
- 330 Health institutions and services 1
Source: the annual accounts at the National Bank. One filing can name more than one committee.
Division 21: Pharmaceuticals
Related activities
2 other activities| Activity | Registrations | Starters, 12 months | Bankruptcies, 12 months | FTE |
|---|---|---|---|---|
| Manufacture of basic pharmaceutical products and pharmaceutical preparations21201 | 149 | 4 | 1 | 25,630 |
| Manufacture of basic pharmaceutical products and pharmaceutical preparations21209 | 97 | 2 | 0 | 1,617 |
Bankruptcies per year in division 21
| Per year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bankruptcies | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 3 | 1 |
| Jobs lost | 1 | 9 | 1 | 1 | 1 | 1 | 1 | 81 | 41 | 109 | 24 |
2026 through April. Every bankruptcy, also of companies that have since left the register. Source: Statbel (Directorate-General Statistics), NACE classification of 2008.
Staff cost per FTE in NACE division 21
104 employers| Size | Median | Middle half | Employers |
|---|---|---|---|
| fewer than 10 FTE | €71,000 | €53,500 to €110,200 | 40 |
| 10 to 49 FTE | €102,100 | €95,100 to €128,700 | 28 |
| 50 to 249 FTE | €82,700 | €74,400 to €95,300 | 21 |
Employers with the highest staff cost per FTE in this division All sectors by staff cost In the Analysis workbench
Foreign control in NACE division 21
309 registered companiesSubsidies in this sector
per register · legal entities with an enterprise number- Flemish subsidies €65.0m awarded
- Federal transfers 1.2m amount as published
- EU budget €15.6m attributed share
- EU research €38.2m EU contribution
Insights on Manufacture of basic pharmaceutical products and pharmaceutical preparations
Balance sheet and result. 27.5% of the annual accounts show negative equity, against 12.4% in Belgium. 44.0% of the annual accounts close with a loss, against 26.7% in Belgium. The median net result of €8,208 is below Belgium's €16,500.
Bankruptcies. The median bankruptcy probability of 0.4% is above Belgium's 0.2%.
Inflow and structure. 6.2% of the companies are sole traders, against 41.6% in Belgium. Wallonia holds 39.7% of the seats, against 22.7% in Belgium. In 12 months, 3.4 of 100 companies started, against 8.9 in Belgium. That is fewer than in 83% of the 87 NACE divisions.
Staff and filing. The 5 largest employers hold 3,041 of the 3,546 FTE: 85.8%.
Direction. Median solvency rose from 32.1% in financial year 2020 to 39.2% in financial year 2025. The median net result fell from €12,702 in financial year 2020 to €8,208 in financial year 2025.
The comparison with Belgium as a whole and with the other divisions is as of 08-11-2026 05:30.
Method and sources
Every company registered today counts under its main activities in the KBO. Establishment units do not count. Staff counts once, under the employer's first main activity, from its latest accounts and only where it fits the staff costs. The count follows the NACE 2025 classification, the version in which code 21100 exists.
The bankruptcies over five years count only companies still registered today, because the activity of a company that left the register is not kept. So they are fewer than the bankruptcies of those years, and the figure is not a probability for the future. Over twelve months the count is nearly complete, because a bankrupt company stays registered while its bankruptcy runs. A company with more than one main activity counts in each of those sectors.
The comparison with Belgium as a whole and with the other NACE divisions rests on an overview of every division, counted again each night. Each division is counted in the version of the NACE classification in which it exists. A standing such as "more than in 80%" compares with the other divisions that have the figure. A division's bankruptcy probability is the median over its companies with a score. Belgium here counts the 1,276,474 companies with a main activity, because only those belong to a division. The other 699,509 registrations publish no activity.
Each median is the value of the middle company, computed over the annual accounts of financial year 2025, and is shown only from 30 accounts. A share (loss-making, negative equity) counts that year's accounts with that trait. Accounts are late when they are filed after the statutory deadline. The direction per financial year follows the companies still registered today. Missing or 90 days late counts the companies with accounts missing today, or whose latest were filed more than 90 days after the deadline. The dossier follows the same rule.